Three insights:
1. DSUVIA, a synthetic opioid tablet, received FDA approval in 2018.
2. The study will explore if DSUVIA is linked with a decrease in pain intensity in the recovery room, opioid consumption and side effects, number of IV fentanyl boluses and hospitalization costs.
3. Richard Urman, MD, associate professor of anesthesia and co-director of the center for perioperative research at BWH and Boston-based Harvard Medical School is leading the study.
More articles on spine:
Rothman Orthopaedics surgeon to lead orthopedic oncology program
New Southeastern Spine Institute moves closer to completion
Kevin Lobo’s 8+ years as Stryker CEO: Leading 20+ acquisitions, boosting robotics & more
